Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: The metabolic effects of polycystic ovary syndrome (PCOS) may increase the risk of non-alcoholic fatty liver disease (NAFLD). However, the burden of NAFLD in PCOS has not been unequivocally defined. This systematic review (SR), meta-analysis (MA) assessed NAFLD’s prevalence, and risk factors in patients with PCOS. Methods: A literature search was performed in MEDLINE, Scopus, and Scielo. First, we performed a MA of proportions to estimate the prevalence of NAFLD in PCOS. Second, we performed meta-analyses of precalculated adjusted odds ratios to examine NAFLD risk factors. Finally, we performed a meta-regression to model how the estimated prevalence changed with changes in prespecified variables. Results: We identified 817 articles from the database searches. Thirty-six were included. MA of proportions found a pooled NAFLD prevalence of 43% (95% CI, 35–52%) with high heterogeneity (I2 = 97.2%). BMI, waist circumference, ALT values, HOMA-IR values, free androgen index levels, hyperandrogenism, and triglycerides were associated with significantly higher risk-adjusted odds of NAFLD among patients with PCOS. Meta-regression showed that rises in NAFLD prevalence were mediated through increases in metabolic syndrome prevalence and higher levels of HOMA-IR, free androgen index, and total testosterone. Conclusion: The prevalence of NAFLD (43%) among PCOS patients is high despite their average young age, with several metabolic and PCOS-specific factors influencing its occurrence. Screening programs may aid in detecting metabolic-associated fatty liver disease and prevent its consequences. Further work is required to establish the burden of liver-related outcomes once NAFLD has progressed in the PCOS population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092
Slim, K., Nini, E., Forestier, D., Kwiatkowski, F., Panis, Y., & Chipponi, J. (2003) · ANZ Journal of Surgery · doi:10.1046/j.1445-2197.2003.02748.x · Cited by 7,603 · cited 5×
“Risk of bias evaluation according to MINORS, 3.”
MethodInfluentialMetaprop: a Stata command to perform meta-analysis of binomial data
Nyaga, V. N., Arbyn, M., & Aerts, M. (2014) · Archives of Public Health · doi:10.1186/2049-3258-72-39 · Cited by 2,139
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029349 · Cited by 1,146 · cited 1×
“The increasing burden of non-alcoholic fatty liver disease (NAFLD), which now is estimated to affect approximately 25% of the global population [1], has become a matter of global concern as the disease comes with a higher risk of other metabolic impairments, including obesity, type 2 diabetes mellitus, and the consequ…”
BackgroundRobinson, K. A., & Dickersin, K. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.150 · Cited by 833
Hunter, J. P., Saratzis, A., Sutton, A. J., Boucher, R. H., Sayers, R. D., & Bown, M. J. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.03.003 · Cited by 786
Melsen, W. G., Bootsma, M. C. J., Rovers, M. M., & Bonten, M. J. M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12494 · Cited by 776 · cited 1×
“In this scenario, methodological studies [66] have demonstrated that a quantitative synthesis is appropriate, even with extreme heterogeneity, such as in this MA.”
BackgroundBarker, T. H., Migliavaca, C. B., Stein, C., Colpani, V., Falavigna, M., Aromataris, E., & Munn, Z. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01381-z · Cited by 738
Cooper, C., Booth, A., Varley-Campbell, J., Britten, N., & Garside, R. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0545-3 · Cited by 561
Polycystic Ovarian Syndrome: Correlation Between Hyperandrogenism, Insulin Resistance and Obesity.
Zeng, X., Xie, Y.-J., Liu, Y.-T., Long, S.-L., & Mo, Z.-C. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.11.003 · Cited by 525
Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome
Wang, J., Wu, D., Guo, H., & Li, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116940 · Cited by 322
Wu, J., Yao, X.-Y., Shi, R.-X., Liu, S.-F., & Wang, X.-Y. (2018) · Reproductive Health · doi:10.1186/s12978-018-0519-2 · Cited by 130
Borruel, S., Fernández-Durán, E., Alpañés, M., Martí, D., Álvarez-Blasco, F., Luque-Ramírez, M., & Escobar-Morreale, H. F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3698 · Cited by 122 · cited 1×
“[49] Borruel 2013 Casecontrol Spain NIH US 106 55 21 NR NR 83 (39) NR 23 (42) NR 88 (20) NR NR 2.”
Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis
Sarkar, M., Terrault, N., Chan, W., Cedars, M. I., Huddleston, H. G., Duwaerts, C. C., Balitzer, D., & Gill, R. M. (2020) · Liver International · doi:10.1111/liv.14279 · Cited by 99
Cited by
Changing epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Stener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., Laven, J., Hoeger, K., & Piltonen, T. T. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00511-3 · Cited by 495
“%) in women with PCOS 53 .”
Vine, D., Ghosh, M., Wang, T., & Bakal, J. (2024) · CJC Open · doi:10.1016/j.cjco.2023.12.010 · Cited by 53
“100,103 Diabetes Our data showed that type 2 diabetes had a 3-fold higher prevalence in those with PCOS in Canada (10% vs 3% in controls), consistent with other epidemiologic studies.”
BackgroundResultVolek, J. S., Kackley, M. L., & Buga, A. (2024) · Current Nutrition Reports · doi:10.1007/s13668-024-00548-6 · Cited by 48
Metadata
- Authors
- Manzano-Nunez, R., Santana-Dominguez, M., Rivera-Esteban, J., Sabiote, C., Sena, E., Bañares, J., Tacke, F., & Pericàs, J. M.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2023-01-20
- Volume
- 12
- Issue
- 3
- Pages
- 856
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W4317810570
- Cited by
- 61
- References
- 15
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.